UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedical Corporation (Exact name of Registrant as specified in its Charter) Delaware (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from Commission File Number: 001-40047 WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction ...

Mark Massaro - BTIG Except required by law, Talis Bio disclaims any intention or obligation to update or revise any financial projection or forward-looking statement whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on August 10th, 2023. Our initial planned test menu consists of a Respiratory Panel for Influenza A, Influenza B in COVID-19 or Fluid, Chlamydia, gonorrhoeae, and Trichomonas vag ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 1100 Island Drive Redwood City, California 94065 (Address of principal executive offices) (Zip Code) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Company Participants Mark Massaro - BTIG Emily Faucette Before we get started, I would like to remind you that management will make remarks during this call that are forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Rob Kelley Despite this, recent research shows that only 56% of these sexually active females have been screened for chlamy ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40047 Talis Biomedical Corporation (Exact name of Registrant as specified in its Charter) Delaware 46-3122255 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-40047 Talis Biomedical Corporation (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction ...

Talis Biomedical Corporation (NASDAQ:TLIS) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Roger Moody - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Mike Ryskin - Bank of America Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call. At this ...